A Study of Ciclesonide Nasal Spray in Patients 18 Years and Older With Seasonal Allergic Rhinitis (BY9010/M1-413)

Phase 3

Completed

• Conditions: Rhinitis, Allergic, Seasonal; Hay Fever

• Registration Number: NCT00384475
• Lead Sponsor: AstraZeneca

Brief Summary

The purpose of this study is to investigate the safety and effectiveness of ciclesonide nasal spray as compared with placebo (inactive substance) nasal spray in relieving symptoms of seasonal allergic rhinitis caused by pollen. Ciclesonide will be administered once during the exposure to ragweed pollen in a controlled environment. The study duration consists of a baseline period (up to 5 days) and a treatment period (1 day). The study will provide further data on safety and tolerability of ciclesonide.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2006-10
• Study First Submitted: 2006-10-05
• Study First Submitted QC: 2006-10-05
• Study First Posted: 2006-10-06
• Primary Completion: 2007-01
• Study Completion: 2007-01
• Status Verified: 2016-10
• Last Update Submitted: 2016-11-29
• Last Update Posted: 2016-11-30

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

• Written informed consent
• General good health
• History of SAR to short ragweed pollen for 2 years immediately preceding the study
• Demonstrated sensitivity to short ragweed known to induce SAR through a standard skin prick test

Main

Read More

Exclusion Criteria

• Clinically significant physical finding of nasal anatomical deformities causing greater than 50% obstruction, including but not limited to nasal polyps, septal defects, respiratory tract malformations, nasal trauma or surgery
• Known hypersensitivity to any corticosteroid
• History of a respiratory infection or disorder including but not limited to bronchitis, pneumonia, chronic sinusitis, influenza or SARS (severe acute respiratory syndrome) within 14 days preceding the Screening Visit
• History of alcohol or drug abuse within 2 years preceding the Screening Visit
• Active asthma requiring treatment of inhaled or systemic corticosteroids and/or routine use of beta-agonists or any controller drugs
• Use of antibiotic therapy for acute conditions within 14 days preceding the Screening Visit
• Exposure to systemic corticosteroids for any indication, chronic or intermittent within 60 days preceding the Screening Visit

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Onset of action, measured by change from baseline in Total Nasal Symptom Score.

Secondary Outcome Measures

Name	Time	Method
changes in symptoms, safety.

Trial Locations

Locations (1)

Altana Pharma/Nycomed; 🇨🇦 Ontario, Mississauga, Canada